Two big Announcements in one day. It's the shape of things to come, my friends.
The IND for Vaxinia was expected, of course, but this is still fabulous news.
It's also further confirmation that the Check-vacc trial is going smoothly, with no problematic toxicity. Check-vacc is derived from the same CF-33 as Vaxinia. There is ZERO chance that the FDA would approve IND for Vaxinia if Check-vacc was showing any problems.
So Imugene is making an impressive double announcement sprint move in the run up to the ASX200 finish line. That's quite a performance.
What's not to love about this?
Cheers
Dave
Ann: FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA, page-24
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
-0.003(6.82%) |
Mkt cap ! $304.9M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.4¢ | 4.1¢ | $1.607M | 38.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 4542680 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.3¢ | 1675759 | 9 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |